EpiAxis Therapeutics recently presented at BioPharm America 2022, part of Biotech Week Boston, giving investors an update on the company’s progress in the epigenetic space.
BioPharm America is a conference where the new wave of life science innovators partner to fuel the future of drug development. Now in its 15th year, the event was held in-person on 28-29 September 2022 and across two digital days from 4-5 October 2022.
BioPharm America Digital created a robust exchange among executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors and academic institutions. It brought dealmakers from the life science ecosystem together, with half the virtual audience from the United States and the rest from around the globe.
Appearing at BioPharm American follows an exciting Q1 FY23 for EpiAxis, which has included collaborations with University Health Network (UHN) and Peptilogics.
EpiAxis and UHN – Canada’s largest and leading research hospital – have entered into a collaboration to study a new approach to prostate cancer treatment; while Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, has joined with EpiAxis to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.
Watch EpiAxis CEO Dr Jeremy Chrisp’s presentation below: